Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 10 Neoplasms 3 Fallopian Tube Neoplasms 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Brain Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 SCLC,Extensive Stage 1 Rare Tumor 1 Penile Neoplasms 1 Pathologic Complete Response 1 Pancreatic Adenocarcinoma Metastatic 1 Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma 1 Ovarian Carcinosarcoma 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Hemangiosarcoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Cystadenocarcinoma, Serous 1 Carcinoma, Ovarian Epithelial 1 Carcinoma 1 Biliary Tract Neoplasms 1 Advanced Solid Tumor 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × niraparib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡